Catalyst Pharmaceuticals (CPRX) Payables (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Payables of $7.2 million for Q1 2026, down 36.13% year-on-year from $11.2 million in Q1 2025, and down 36.16% on a QoQ basis from $11.2 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Payables data on file, last reported at $7.2 million in Q1 2026.
- For the quarter ending Q1 2026, Payables fell 36.13% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (down 36.13% YoY), and the FY2025 full-year result was $11.2 million, down 32.49% from the prior year.
- Payables for Q1 2026 stood at $7.2 million, down from $11.2 million in the prior quarter.
- Across five years, Payables topped out at $16.6 million in Q4 2024 and bottomed at $2.3 million in Q2 2022.
- The 5-year median for Payables is $7.1 million (2024), against an average of $7.7 million.
- The widest annual swing landed in 2023, when Payables soared 272.2%; it then slumped 36.13% in 2026.
- A 5-year view of Payables shows it stood at $4.0 million in 2022, then jumped by 272.2% to $14.8 million in 2023, then climbed by 12.15% to $16.6 million in 2024, then tumbled by 32.49% to $11.2 million in 2025, then sank by 36.16% to $7.2 million in 2026.
- The last three Payables figures came in at $7.2 million (Q1 2026), $11.2 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 7.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.15 Mn |
| Dec 31, 2025 | 11.20 Mn |
| Sep 30, 2025 | 9.10 Mn |
| Jun 30, 2025 | 5.53 Mn |
| Mar 31, 2025 | 11.20 Mn |
| Dec 31, 2024 | 16.59 Mn |
| Sep 30, 2024 | 11.56 Mn |
| Jun 30, 2024 | 7.12 Mn |
| Mar 31, 2024 | 10.26 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 4.60 Mn |
| Jun 30, 2023 | 4.42 Mn |
| Mar 31, 2023 | 3.39 Mn |
| Dec 31, 2022 | 3.98 Mn |
| Sep 30, 2022 | 2.53 Mn |
| Jun 30, 2022 | 2.32 Mn |
| Mar 31, 2022 | 5.14 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Sep 30, 2021 | 2.75 Mn |
| Jun 30, 2021 | 2.92 Mn |
| Mar 31, 2021 | 2.56 Mn |
| Dec 31, 2020 | 4.26 Mn |
| Sep 30, 2020 | 2.01 Mn |
| Jun 30, 2020 | 5.80 Mn |
| Mar 31, 2020 | 1.35 Mn |
| Dec 31, 2019 | 4.12 Mn |
| Sep 30, 2019 | 4.15 Mn |
| Jun 30, 2019 | 3.33 Mn |
| Mar 31, 2019 | 2.94 Mn |
| Dec 31, 2018 | 2.34 Mn |
| Sep 30, 2018 | 1.34 Mn |
| Jun 30, 2018 | 922,593.00 |
| Mar 31, 2018 | 805,023.00 |
| Dec 31, 2017 | 1.95 Mn |
| Sep 30, 2017 | 1.08 Mn |
| Jun 30, 2017 | 692,345.00 |
| Mar 31, 2017 | 917,928.00 |
| Dec 31, 2016 | 933,176.00 |
| Sep 30, 2016 | 1.06 Mn |
| Jun 30, 2016 | 707,292.00 |
| Mar 31, 2016 | 1.25 Mn |
| Dec 31, 2015 | 1.79 Mn |
| Sep 30, 2015 | 1.57 Mn |
| Jun 30, 2015 | 1.32 Mn |
| Mar 31, 2015 | 1.05 Mn |
| Dec 31, 2014 | 1.81 Mn |
| Sep 30, 2014 | 524,795.00 |
| Jun 30, 2014 | 1.24 Mn |
| Mar 31, 2014 | 932,105.00 |
| Dec 31, 2013 | 850,789.00 |
| Sep 30, 2013 | 1.47 Mn |
| Jun 30, 2013 | 448,282.00 |
| Dec 31, 2012 | 1.37 Mn |
| Mar 31, 2012 | 350,329.00 |
| Dec 31, 2011 | 263,934.00 |
| Sep 30, 2011 | 174,038.00 |
| Jun 30, 2011 | 478,011.00 |
| Dec 31, 2010 | 105,933.00 |